Danish Guidelines for Lipid-lowering Treatment in Patients with Chronic Renal Failure

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Danish Guidelines for Lipid-lowering Treatment in Patients with Chronic Renal Failure. / Dieperink, Hans; Christensen, Jeppe Hagstrup; Feldt-Rasmussen, Bo; Schmidt, Erik Berg; Danish Society of Cardiology.

I: Danish Medical Journal, Bind 61, Nr. 4, C4843, 04.2014, s. 1-5.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Dieperink, H, Christensen, JH, Feldt-Rasmussen, B, Schmidt, EB & Danish Society of Cardiology 2014, 'Danish Guidelines for Lipid-lowering Treatment in Patients with Chronic Renal Failure', Danish Medical Journal, bind 61, nr. 4, C4843, s. 1-5.

APA

Dieperink, H., Christensen, J. H., Feldt-Rasmussen, B., Schmidt, E. B., & Danish Society of Cardiology (2014). Danish Guidelines for Lipid-lowering Treatment in Patients with Chronic Renal Failure. Danish Medical Journal, 61(4), 1-5. [C4843].

Vancouver

Dieperink H, Christensen JH, Feldt-Rasmussen B, Schmidt EB, Danish Society of Cardiology. Danish Guidelines for Lipid-lowering Treatment in Patients with Chronic Renal Failure. Danish Medical Journal. 2014 apr;61(4):1-5. C4843.

Author

Dieperink, Hans ; Christensen, Jeppe Hagstrup ; Feldt-Rasmussen, Bo ; Schmidt, Erik Berg ; Danish Society of Cardiology. / Danish Guidelines for Lipid-lowering Treatment in Patients with Chronic Renal Failure. I: Danish Medical Journal. 2014 ; Bind 61, Nr. 4. s. 1-5.

Bibtex

@article{999e181ab0984d34813488911c414fe3,
title = "Danish Guidelines for Lipid-lowering Treatment in Patients with Chronic Renal Failure",
abstract = "Measurement of lipid profile in adults with CKD 1-5: We recommend measuring the lipid profile (T cholesterol, LDL cholesterol, HDL cholesterol and triglycerides) in all adults with newly diagnosed CKD 1-5 (including patients in renal replacement therapy). Monitoring of lipid profile in adults with CKD 1-5: In many cases it is not necessary to regularly monitor the lipid profile. Patients ≥ 50 years with CKD 1-5 ND: We recommend that these patients be treated with a statin (CKD 1-2, evidence level B), and in CKD patients in stages 3-5 ND that a statin or the combination statin/ezetimibe be used (evidence level A). Patients aged 18-49 years with CKD 1-5 ND: We suggest treating these patients with a statin if they also have one or more of the following conditions (evidence level A): known CVD, DM, Prior ischaemic stroke, Estimated 10-year risk of coronary death or non-fatal AMI > 10 {\%} or risk of fatal cardiovascular disease > 5{\%} (SCORE). Patients with CKD stage 5D: We suggest that these patients not be given a statin or started on statin/ezetimibe treatment (evidence level A). Patients who start dialysis and are already being treated with a statin or statin/ezetimibe: We suggest that treatment be continued (evidence level C). Adult kidney transplanted patients: We suggest that these patients be treated with a statin (evidence level B).",
keywords = "Cardiovascular Diseases, Comorbidity, Denmark, Diabetic Angiopathies, Diabetic Nephropathies, Dyslipidemias, Humans, Hypolipidemic Agents, Kidney Failure, Chronic, Kidney Transplantation, Renal Dialysis",
author = "Hans Dieperink and Christensen, {Jeppe Hagstrup} and Bo Feldt-Rasmussen and Schmidt, {Erik Berg} and {Danish Society of Cardiology}",
year = "2014",
month = "4",
language = "English",
volume = "61",
pages = "1--5",
journal = "Danish Medical Journal",
issn = "1603-9629",
publisher = "Almindelige Danske Laegeforening",
number = "4",

}

RIS

TY - JOUR

T1 - Danish Guidelines for Lipid-lowering Treatment in Patients with Chronic Renal Failure

AU - Dieperink, Hans

AU - Christensen, Jeppe Hagstrup

AU - Feldt-Rasmussen, Bo

AU - Schmidt, Erik Berg

AU - Danish Society of Cardiology

PY - 2014/4

Y1 - 2014/4

N2 - Measurement of lipid profile in adults with CKD 1-5: We recommend measuring the lipid profile (T cholesterol, LDL cholesterol, HDL cholesterol and triglycerides) in all adults with newly diagnosed CKD 1-5 (including patients in renal replacement therapy). Monitoring of lipid profile in adults with CKD 1-5: In many cases it is not necessary to regularly monitor the lipid profile. Patients ≥ 50 years with CKD 1-5 ND: We recommend that these patients be treated with a statin (CKD 1-2, evidence level B), and in CKD patients in stages 3-5 ND that a statin or the combination statin/ezetimibe be used (evidence level A). Patients aged 18-49 years with CKD 1-5 ND: We suggest treating these patients with a statin if they also have one or more of the following conditions (evidence level A): known CVD, DM, Prior ischaemic stroke, Estimated 10-year risk of coronary death or non-fatal AMI > 10 % or risk of fatal cardiovascular disease > 5% (SCORE). Patients with CKD stage 5D: We suggest that these patients not be given a statin or started on statin/ezetimibe treatment (evidence level A). Patients who start dialysis and are already being treated with a statin or statin/ezetimibe: We suggest that treatment be continued (evidence level C). Adult kidney transplanted patients: We suggest that these patients be treated with a statin (evidence level B).

AB - Measurement of lipid profile in adults with CKD 1-5: We recommend measuring the lipid profile (T cholesterol, LDL cholesterol, HDL cholesterol and triglycerides) in all adults with newly diagnosed CKD 1-5 (including patients in renal replacement therapy). Monitoring of lipid profile in adults with CKD 1-5: In many cases it is not necessary to regularly monitor the lipid profile. Patients ≥ 50 years with CKD 1-5 ND: We recommend that these patients be treated with a statin (CKD 1-2, evidence level B), and in CKD patients in stages 3-5 ND that a statin or the combination statin/ezetimibe be used (evidence level A). Patients aged 18-49 years with CKD 1-5 ND: We suggest treating these patients with a statin if they also have one or more of the following conditions (evidence level A): known CVD, DM, Prior ischaemic stroke, Estimated 10-year risk of coronary death or non-fatal AMI > 10 % or risk of fatal cardiovascular disease > 5% (SCORE). Patients with CKD stage 5D: We suggest that these patients not be given a statin or started on statin/ezetimibe treatment (evidence level A). Patients who start dialysis and are already being treated with a statin or statin/ezetimibe: We suggest that treatment be continued (evidence level C). Adult kidney transplanted patients: We suggest that these patients be treated with a statin (evidence level B).

KW - Cardiovascular Diseases

KW - Comorbidity

KW - Denmark

KW - Diabetic Angiopathies

KW - Diabetic Nephropathies

KW - Dyslipidemias

KW - Humans

KW - Hypolipidemic Agents

KW - Kidney Failure, Chronic

KW - Kidney Transplantation

KW - Renal Dialysis

M3 - Journal article

C2 - 24814603

VL - 61

SP - 1

EP - 5

JO - Danish Medical Journal

JF - Danish Medical Journal

SN - 1603-9629

IS - 4

M1 - C4843

ER -

ID: 138384552